[Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias]. 1991

M C Bertolami, and T L Martinez, and A A Faludi, and L E Pinto, and R S Melo, and Z F Bismarck, and M Batlouni
Instituto Dante Pazzanese de Cardiologia, Escola Paulista de Medicina, São Paulo.

OBJECTIVE To compare the effects of lovastatin and gemfibrozil in patients with primary hyperlipidemias. METHODS Forty patients with cholesterolemia over 200 mg/dl and triglyceridemia not higher than 350 mg/dl, excluded secondary causes, were selected. Twenty patients received lovastatin and 20 gemfibrozil. In order to establish the lipid profile, blood samples were taken after 2 months without medication, after 4 weeks of diet and placebo and after 6 and 12 weeks of active treatment. Biochemical profile was determined before and after the treatment with active drug. RESULTS Thirty nine patients completed the study. Total and LDL-cholesterol were significantly reduced (p less than 0.05) by both drugs but lovastatin had greater effect. Only gemfibrozil reduced triglycerides significantly. Neither drug had significant effects on HDL-cholesterol. The tolerance was satisfactory; only one patient (using gemfibrozil) needed to stop the treatment due to gastrointestinal side effects. The biochemical profile did not present any significant alteration. CONCLUSIONS Both drugs produced useful effects on the lipid profile. Lovastatin produced greater reductions of total and LDL-cholesterol, while gemfibrozil was more active reducing triglycerides. Neither drug changed significantly the HDL-cholesterol.

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008148 Lovastatin A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver. Lovastatin, 1 alpha-Isomer,Mevinolin,6-Methylcompactin,Lovastatin, (1 alpha(S*))-Isomer,MK-803,Mevacor,Monacolin K,1 alpha-Isomer Lovastatin,6 Methylcompactin,Lovastatin, 1 alpha Isomer,MK 803,MK803,alpha-Isomer Lovastatin, 1
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006937 Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population. Hypercholesteremia,Elevated Cholesterol,High Cholesterol Levels,Cholesterol Level, High,Cholesterol Levels, High,Cholesterol, Elevated,Cholesterols, Elevated,Elevated Cholesterols,High Cholesterol Level,Hypercholesteremias,Hypercholesterolemias,Level, High Cholesterol,Levels, High Cholesterol

Related Publications

M C Bertolami, and T L Martinez, and A A Faludi, and L E Pinto, and R S Melo, and Z F Bismarck, and M Batlouni
January 1992, The American journal of cardiology,
M C Bertolami, and T L Martinez, and A A Faludi, and L E Pinto, and R S Melo, and Z F Bismarck, and M Batlouni
November 1988, The American journal of cardiology,
M C Bertolami, and T L Martinez, and A A Faludi, and L E Pinto, and R S Melo, and Z F Bismarck, and M Batlouni
July 1992, The American journal of cardiology,
M C Bertolami, and T L Martinez, and A A Faludi, and L E Pinto, and R S Melo, and Z F Bismarck, and M Batlouni
January 1992, Revista de medicina de la Universidad de Navarra,
M C Bertolami, and T L Martinez, and A A Faludi, and L E Pinto, and R S Melo, and Z F Bismarck, and M Batlouni
January 1990, Cardiology,
M C Bertolami, and T L Martinez, and A A Faludi, and L E Pinto, and R S Melo, and Z F Bismarck, and M Batlouni
December 1989, JAMA,
M C Bertolami, and T L Martinez, and A A Faludi, and L E Pinto, and R S Melo, and Z F Bismarck, and M Batlouni
December 1991, Atherosclerosis,
M C Bertolami, and T L Martinez, and A A Faludi, and L E Pinto, and R S Melo, and Z F Bismarck, and M Batlouni
February 1993, The American journal of cardiology,
M C Bertolami, and T L Martinez, and A A Faludi, and L E Pinto, and R S Melo, and Z F Bismarck, and M Batlouni
May 1990, The Journal of laboratory and clinical medicine,
M C Bertolami, and T L Martinez, and A A Faludi, and L E Pinto, and R S Melo, and Z F Bismarck, and M Batlouni
June 1993, The American journal of cardiology,
Copied contents to your clipboard!